Global Renal Anemia Treatment Market 2023: Development of Novel HIF Stabilizers & Approval of Cost-effective Biosimilar Drugs Expected to Push Growth

The renal anemia treatment market is growing rapidly with huge potential for growth as the use of this technology increases across both developed and emerging economies. Renal anemia is a condition where there is an inadequate production of red blood cells due to reduced levels of circulating erythropoietin (EPO) hormone in the body, usually occurring as a result of chronic kidney disease or failure. Common treatments for renal anemia include recombinant human EPO (rHuEPO) therapy, iron supplements and in some cases, blood transfusions.

This impressive growth trend can be attributed to healthcare advancements being made within this space such as improved rHuEPO molecules catering towards individual patient needs thus driving up success rates greatly; something which has been amplified recently due increasing adoption rates amongst developing countries due higher availability treatments previously not accessible these regions before. In addition, there continues be push towards creating next generation products utilising AI technologies providing clinicians better access medical information helpful when deciding suitable interventions suitably tailored towards particular patient needs thus enabling higher success rates than ever before imaginable when it comes managing associated symptoms from kidney disorders effectively.

Request For Free Sample Report of "Renal Anemia Treatment Market"@ https://www.persistencemarketresearch.com/samples/27115

Renal Anemia Treatment Market: Key Dynamics

The global burden of chronic kidney disease continues to increase throughout the globe, which is driving the growth of the renal anemia treatment market. According to the National Kidney Foundation, 10% of the population worldwide is affected by the chronic kidney disease (CKD), which in turn, has increased the patient pool for renal anemia treatment. Increasing cases of chronic kidney disease and increasing prevalence of diabetes and hyper tension will push the market of renal anemia treatment in near future.

Additionally, the development and identification of novel HIF stabilizers is likely to change the pathway for renal anemia treatment in near future. HIF stabilizers under clinical trial hold promise as they provide a unique modality for renal anemia treatment through novel mechanisms of action. There are currently 4 HIF stabilizers that are in phase 2/3 clinical trials (roxadustat, daprodustat, vadadustat, and molidustat) and all of these are orally administered agents which will create huge opportunities for the growth of the renal anemia treatment market during the forecast period.

Buy Full Report Now @ https://www.persistencemarketresearch.com/checkout/27115

Companies

Amgen Inc.
Vifor Pharma Management Ltd.
Hoffmann-La Roche Ltd
Pfizer Inc.
Sandoz International GmbH (Novartis AG)
Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
Teva Pharmaceutical Industries Ltd.
AMAG Pharmaceuticals
Rockwell Medical
Akebia Therapeutics

On the other side, drugs for renal anemia treatment come with a huge price tag. Even the good health insurance benefits do not necessarily cover biologics and thus, the out-of-pocket expenditure is too high. High cost for renal anemia treatment is, thus, the biggest factor that limits the treatment seeking rate with biologics and in turn, negatively impacts the growth of the renal anemia treatment market. Moreover, long-term renal anemia treatment with erythropoiesis-stimulating agents (ESAs) has been associated with increased systemic blood pressure and occurrence of seizures.

Hypertension is a common side effect of intravenous use of erythropoiesis-stimulating agents. A significant side effect of erythropoiesis-stimulating agents is increased risk of thromboembolic complications. Also, in patients with cancer, erythropoiesis-stimulating agents cause the tumor to grow. Therefore, the many side effects associated with the use of erythropoiesis-stimulating agents might hinder the growth of the renal anemia treatment market in the near future.

Erythrocyte stimulating agents and iron supplements are used in combination for renal anemia treatment. Among both product types, erythrocyte stimulating agents are estimated to gain major market revenue share in the global renal anemia treatment market due to their high price tag. The drugs for renal anemia treatment are available in both oral and injectable forms in the market. However, the injectable drugs are more preferred by doctors for renal anemia treatment and hence, by route of administration, the parenteral segment holds the majority share of the global renal anemia treatment market, in terms of revenue.

Among all distribution channels, the hospital pharmacies segment is expected to be most dominant segment in global renal anemia treatment market and will be followed by retail pharmacies. The mail order pharmacies segment is expected grow at a fast pace in the renal anemia treatment market.

Request Customization @ https://www.persistencemarketresearch.com/request-customization/27115

Key Questions Answered in This Report.

What are the Roadblocks for Renal Anemia Treatment Market Suppliers?
What are the Key Opportunities for Renal Anemia Treatment Market Manufacturers?
How is Focus on Safety Influencing Renal Anemia Treatment Market Demand?
What is the Regulatory Impact on Global Sales of Renal Anemia Treatment Market?
Which Region Offers the Largest Opportunity for Sales of Renal Anemia Treatment Market?
Where Does the U.S. Stand in the Market for Renal Anemia Treatment Market?
What Is the Outlook for Renal Anemia Treatment Market Manufacturers in China?
Why is Germany a Lucrative Market for Renal Anemia Treatment Market Manufacturers?
Why Will Belgium Outpace Other European Markets for Renal Anemia Treatment Market?
Why is There High Demand for Tires in Renal Anemia Treatment Market?
Why are Sales of Renal Anemia Treatment Market Surging?

Related Market Research Reports:

For More Premium Insights, Check out the Link:

Primary Hepatocytes Market - https://www.persistencemarketresearch.com/market-research/primary-hepatocytes-market.asp

Oncology Mice Models Market - https://www.prnewswire.com/news-releases/oncology-mice-models-market-with-an-estimated-growth-rate-of-6-over-the-decade-persistence-market-research-301531935.html

Asean Dysphagia Diet Thickening Agents Market - https://www.persistencemarketresearch.com/market-research/asean-dysphagia-diet-thickening-agents-market.asp

Xerostomia Dry Mouth Treatment Market - https://www.prnewswire.com/news-releases/xerostomia-dry-mouth-treatment-market-is-set-to-exhibit-growth-at-a-cagr-of-6-1-to-reach-us-1-81-bn-by-2032---persistence-market-research-301523681.html

Electrophysiology Ablation Market - https://www.persistencemarketresearch.com/market-research/electrophysiology-ablation-market.asp

Media Contact:
Persistence Market Research
305 Broadway,7th Floor New York City, NY 10007 United States
Call +1-646-568-7751
Call +1 800-961-0353
sales@persistencemarketresearch.com

About Us

Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.

This release was published on openPR.